Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Institutional investor

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 14, 2023 9:30pm

165 Views

Post# 35735925

RE:RE:RE:RE:RE:RE:RE:Institutional investor

As late as October 19th 2023 this is who invested in onc. Did onc do their own dd on Anson.

SEC Charges Canadian Investment Adviser with Violating Trading Rule

ADMINISTRATIVE PROCEEDING
File No. 3-21783

October 19, 2023 - The Securities and Exchange Commission today announced settled charges against Canada-based Anson Advisors Inc. ("AAI") for violating an SEC trading rule when it purchased stock in three public offerings for private fund clients after selling short the same stock for private fund clients, during a time period when the SEC rule prohibited those purchases.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle